公开(公告)号：US20150056630A1

公开(公告)日：2015-02-26

申请号：US14388609

申请日：2013-04-02

Applicant: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT ,  NIPPON ZOKI PHARMACEUTICAL CO., LTD.

Inventor： Hiroshi Asahara ,  Satoshi Yamashita ,  Mitsuru Naiki ,  Kentaro Abe

IPC: G01N33/53 ,  C12N15/113

CPC classification number: G01N33/5308 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/03 ,  C12N15/113 ,  C12N2310/141 ,  G01N2400/10 ,  G01N2500/02 ,  G01N2500/04 ,  G01N2500/10

Abstract: An object of the present invention is to provide DNA which regulates the expression of miR-140, a reporter vector which contains the DNA, cells and animals into which the reporter vector is introduced and a screening system for drugs which control the expression of miR-140 and is also to contribute in the development of new therapeutic agents for cartilage diseases such as osteoarthritis and intervertebral disk degeneration using the screening system. The DNA sequence according to the present invention is able to express any gene in a site where miR-140 is expressed and, in addition, it is also able to be utilized for screening a drug which regulates the expression of miR-140. Moreover, the drug that is selected by the screening system of the present invention is expected as a therapeutic agent for cartilage diseases accompanied by abnormality of cartilage.

Abstract translation: 本发明的目的是提供调节miR-140表达的DNA，该载体包含引入报道载体的DNA，细胞和动物以及控制miR-140表达的药物的筛选系统， 并且还利用筛选系统为软骨疾病如骨关节炎和椎间盘退变的新治疗剂的开发作出贡献。 根据本发明的DNA序列能够在miR-140表达的位点中表达任何基因，此外，它还能够用于筛选调节miR-140表达的药物。 此外，预期本发明的筛选系统选择的药物是软骨异常伴随软骨疾病的治疗剂。

公开(公告)号：US20040214231A1

公开(公告)日：2004-10-28

申请号：US10611310

申请日：2003-07-01

Applicant: Genox Research, Inc. ,  Japan as Rep. by General Director of Agency of National Center for Child Health and Development

Inventor： Ryoichi Hashida ,  Shinji Kagaya ,  Yuji Sugita ,  Hirohisa Saito

IPC: C12Q001/68 ,  G01N033/53

CPC classification number: C07K14/70567 ,  A01K2217/075 ,  A61K31/5575 ,  A61K38/00 ,  G01N2500/10

Abstract: Differential expression of genes whose expression is different in the activated eosinophils of atopic dermatitis patients was measured by comparative analysis using a gene chip. As a result, the TR3 and TINUR genes, whose expression is significantly elevated in activated eosinophils, were successfully identified. The present inventors discovered that these genes can be used to test for allergic disease and to screen candidate compounds for therapeutic agents for allergic disease.

Abstract translation: 通过使用基因芯片的比较分析来测定特应性皮炎患者的活化嗜酸性粒细胞中表达不同的基因的差异表达。 结果，TR3和TINUR基因在活化嗜酸性粒细胞中的表达显着升高。 本发明人发现，这些基因可用于测试过敏性疾病并筛选用于过敏性疾病的治疗剂的候选化合物。

公开(公告)号：US20250163185A1

公开(公告)日：2025-05-22

申请号：US18516127

申请日：2023-11-21

Applicant: HUBIT GENOMIX, INC. ,  NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT

Inventor： Hirohisa SAITO ,  Kenji MATSUMOTO ,  Hideaki MORITA ,  Go ICHIEN ,  Yasuhiko KOEZUKA ,  Kimishige ISHIZAKA

IPC: C07K16/42 ,  A61P37/08

Abstract: The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof

公开(公告)号：US20200246369A1

公开(公告)日：2020-08-06

申请号：US16491435

申请日：2018-03-09

Applicant: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT ,  HIROSHIMA UNIVERSITY ,  DAIICHI SANKYO COMPANY, LIMITED

Inventor： Go TAJIMA ,  Satoshi OKADA ,  Myyuki TSUMURA

IPC: A61K31/7088 ,  C12N15/113 ,  A61P3/08

Abstract: The present invention provides a novel antisense oligonucleotide and a composition for preventing or treating glycogen storage disease type Ia. The present invention provides an antisense oligonucleotide which hybridizes with a pre-mRNA sequence derived from a region including at least one of a base at position 42911000, a base at position 42911004, and a base at position 42911005 in a base sequence of human chromosome 17 of GRCh38/hg38 and has activity to inhibit aberrant splicing of pre-mRNA of c.648G>T variant G6PC.

公开(公告)号：US20180214494A1

公开(公告)日：2018-08-02

申请号：US15881302

申请日：2018-01-26

Applicant: National Center for Child Health and Development

Inventor： Yukihiro OHYA ,  Shigenori KABASHIMA ,  Osamu NATSUME ,  Hirohisa SAITO

IPC: A61K35/57 ,  A61P43/00 ,  A61K9/00

CPC classification number: A61K35/57 ,  A61K9/0095 ,  A61K38/17 ,  A61P43/00

Abstract: The present invention provides an egg allergy prevention method to be carried out with respect to a human infant, including: a first administration period (first administration step) in which to administer, to an infant, heated egg white protein in an amount of 10 mg to 20 mg per day; and a second administration period (second administration step) which is a period after the first administration period and in which to administer, to the infant, the heated egg white protein in an amount of 65 mg to 90 mg per day.

公开(公告)号：US09901558B2

公开(公告)日：2018-02-27

申请号：US15064892

申请日：2016-03-09

Applicant: SBI Pharmaceuticals Co., Ltd. ,  National Center for Child Health and Development

Inventor： Ko Rii ,  Kiwamu Takahashi ,  Naomi Haga ,  Fuminori Abe ,  Tohru Tanaka ,  Motowo Nakajima ,  Hidenori Ito

IPC: A61K31/195 ,  A61K31/197 ,  A61K33/26 ,  A61K31/22 ,  A61K31/295 ,  A61K45/06 ,  A01N1/02 ,  A61K35/17 ,  A61K35/12

CPC classification number: A61K31/197 ,  A01N1/0226 ,  A61K31/22 ,  A61K31/295 ,  A61K33/26 ,  A61K35/17 ,  A61K45/06 ,  A61K2035/122 ,  A61K2035/124 ,  A61K2300/00

Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.

公开(公告)号：US09557327B2

公开(公告)日：2017-01-31

申请号：US14388609

申请日：2013-04-02

Applicant: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT ,  NIPPON ZOKI PHARMACEUTICAL CO., LTD.

Inventor： Hiroshi Asahara ,  Satoshi Yamashita ,  Mitsuru Naiki ,  Kentaro Abe

IPC: C12N15/11 ,  G01N33/53 ,  C12N15/113 ,  A01K67/027

CPC classification number: G01N33/5308 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/03 ,  C12N15/113 ,  C12N2310/141 ,  G01N2400/10 ,  G01N2500/02 ,  G01N2500/04 ,  G01N2500/10

Abstract: An object of the present invention is to provide DNA which regulates the expression of miR-140, a reporter vector which contains the DNA, cells and animals into which the reporter vector is introduced and a screening system for drugs which control the expression of miR-140 and is also to contribute in the development of new therapeutic agents for cartilage diseases such as osteoarthritis and intervertebral disk degeneration using the screening system. The DNA sequence according to the present invention is able to express any gene in a site where miR-140 is expressed and, in addition, it is also able to be utilized for screening a drug which regulates the expression of miR-140. Moreover, the drug that is selected by the screening system of the present invention is expected as a therapeutic agent for cartilage diseases accompanied by abnormality of cartilage.

Abstract translation: 本发明的目的是提供调节miR-140表达的DNA，该载体包含引入报道载体的DNA，细胞和动物以及控制miR-140表达的药物的筛选系统， 并且还利用筛选系统为软骨疾病如骨关节炎和椎间盘退变的新治疗剂的开发作出贡献。 根据本发明的DNA序列能够在miR-140表达的位点中表达任何基因，此外，它还能够用于筛选调节miR-140表达的药物。 此外，预期本发明的筛选系统选择的药物是软骨异常伴随软骨疾病的治疗剂。

公开(公告)号：US12275958B2

公开(公告)日：2025-04-15

申请号：US16713808

申请日：2019-12-13

Applicant: DAI NIPPON PRINTING CO., LTD. ,  NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT

Inventor： Takuya Okazaki ,  Akihiro Umezawa ,  Hidenori Akutsu ,  Hajime Uchida

IPC: C12N5/071 ,  G01N33/50

Abstract: A gut organoid includes a tissue structure that encloses a cavity. A method of using the gut organoid includes providing a test drug to the gut organoid in the presence of a buffer solution so that liquid comprising the test drug enters into the cavity, and collecting and analyzing the liquid in the cavity. A method for producing the gut organoid includes plating cells on a cell culture substrate including a surface on which a cell-adhesive region and a non-cell-adhesive region surrounding the cell-adhesive region are formed, and culturing the cells plated on the cell culture substrate so as to induce differentiation of the cells.

公开(公告)号：US20240101711A1

公开(公告)日：2024-03-28

申请号：US18516082

申请日：2023-11-21

Applicant: HUBIT GENOMIX, INC. ,  NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT

Inventor： Hirohisa SAITO ,  Kenji MATSUMOTO ,  Hideaki MORITA ,  Go ICHIEN ,  Yasuhiko KOEZUKA ,  Kimishige ISHIZAKA

IPC: C07K16/42 ,  A61P37/08

CPC classification number: C07K16/4291 ,  A61P37/08

Abstract: The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof.

公开(公告)号：US20230091310A1

公开(公告)日：2023-03-23

申请号：US17788908

申请日：2020-12-25

Applicant: National Center for Child Health and Development

Inventor： Kenji Miyado ,  Yoshitaka Miyamoto

IPC: A01N1/02 ,  A61K31/4164 ,  C12N5/073

Abstract: Provided is a novel means of inhibiting fertilized egg fragmentation. The present invention provides an inhibitor of fertilized egg fragmentation, said inhibitor comprising selenoneine or ergothioneine, a tautomer or dimer thereof, or a pharmaceutically acceptable salt of the same as an active agent.